IMMATICS NV (IMTX)

NL0015285941 - Common Stock

11  -0.1 (-0.9%)

News Image
7 days ago - InvestorPlace

IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023

IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

News Image
7 days ago - BusinessInsider

IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immatics (NASDAQ:IMTX) just reported results for the fourth quarter of 2023.Imm...

News Image
7 days ago - Chartmill

What's going on in today's pre-market session

Thursday's pre-market session: top gainers and losers

News Image
7 days ago - https://immatics.com/

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median...

News Image
2 months ago - https://immatics.com/

Immatics Announces Pricing of $175 Million Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...

News Image
2 months ago - Seeking Alpha

Immatics commences public offering of shares (NASDAQ:IMTX)

Biopharmaceutical company Immatics has announced an underwritten public offering of shares, without disclosing the size or terms of the offering.

News Image
2 months ago - https://immatics.com/

Immatics Announces Proposed Public Offering

News Image
2 months ago - https://immatics.com/

Immatics Announces Proposed Public Offering

Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...

News Image
2 months ago - DISCO Pharmaceuticals

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....

News Image
5 months ago - Seeking Alpha

Immatics GAAP EPS of -$0.32 beats by $0.07, revenue of $5.93M misses by $6M (NASDAQ:IMTX)

Immatics reports Q3 GAAP EPS of -$0.32, beating estimates by $0.07. Revenue of $5.93M misses by $6M.

News Image
5 months ago - https://immatics.com/

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at...

News Image
5 months ago - https://immatics.com/

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the...

News Image
5 months ago - https://immatics.com/

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

  RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer...

News Image
6 months ago - Market News Video

Relative Strength Alert For Immatics

News Image
7 months ago - Protalix Biotherapeutics Inc.

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

News Image
7 months ago - Seeking Alpha

Immatics GAAP EPS of -€0.32, revenue of €22.4M (NASDAQ:IMTX)

Immatics press release (IMTX): Q2 GAAP EPS of -€0.32.Revenue of €22.4M (+30.2% Y/Y).Cash and cash equivalents as well as other financial assets not including the recent equity...

News Image
7 months ago - https://immatics.com/

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting...

News Image
7 months ago - Immatics N.V.

Immatics veröffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschäftsentwicklung

Klinische Phase-1/2-Studie zur Untersuchung von Immatics‘ zweitem bispezifischen TCR-Programm der nächsten Generation mit verlängerter Halbwertszeit, TCER®...

News Image
8 months ago - https://immatics.com/

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2...

News Image
8 months ago - Immatics N.V.

Immatics beginnt klinische Phase-1/2-Studie zur Untersuchung des bispezifischen TCR-Kandidaten IMA402 gegen die Zielstruktur PRAME bei Patienten mit fortgeschrittenen soliden Tumoren

TCER® IMA402 ist der erste gegen die Zielstruktur PRAME gerichtete bispezifische TCR-Kandidat der nächsten Generation mit verlängerter Halbwertszeit in der...

News Image
8 months ago - Seeking Alpha

Immatics climbs 8% on $35M investment by Bristol Myers Squibb (NASDAQ:IMTX)

A clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, Immatics (IMTX) stock price surged 8.3% on Monday as...

News Image
8 months ago - https://immatics.com/

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the...

News Image
8 months ago - Immatics N.V.

Immatics gibt $35 Millionen Kapitalbeteiligung von Bristol Myers Squibb bekannt

Tübingen, Deutschland und Houston, Texas, 24. Juli 2023 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und...